GB201608052D0 - T-cell receptors which recognise frameshift mutants of TGF-beta RII - Google Patents

T-cell receptors which recognise frameshift mutants of TGF-beta RII

Info

Publication number
GB201608052D0
GB201608052D0 GBGB1608052.5A GB201608052A GB201608052D0 GB 201608052 D0 GB201608052 D0 GB 201608052D0 GB 201608052 A GB201608052 A GB 201608052A GB 201608052 D0 GB201608052 D0 GB 201608052D0
Authority
GB
United Kingdom
Prior art keywords
recognise
tgf
cell receptors
beta rii
frameshift mutants
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1608052.5A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oslo Universitetssykehus hf
Original Assignee
Oslo Universitetssykehus hf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oslo Universitetssykehus hf filed Critical Oslo Universitetssykehus hf
Priority to GBGB1608052.5A priority Critical patent/GB201608052D0/en
Publication of GB201608052D0 publication Critical patent/GB201608052D0/en
Priority to MX2018013581A priority patent/MX2018013581A/es
Priority to KR1020187035676A priority patent/KR20190016507A/ko
Priority to JP2018559282A priority patent/JP2019517790A/ja
Priority to SG11201809716VA priority patent/SG11201809716VA/en
Priority to EP17725537.9A priority patent/EP3455249B1/en
Priority to US16/099,329 priority patent/US20190336529A1/en
Priority to CA3024555A priority patent/CA3024555A1/en
Priority to AU2017261684A priority patent/AU2017261684A1/en
Priority to PCT/EP2017/061087 priority patent/WO2017194555A1/en
Priority to EA201892217A priority patent/EA201892217A1/ru
Priority to CN201780038176.8A priority patent/CN109328196B/zh
Priority to IL262873A priority patent/IL262873A/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4225—Growth factors
    • A61K40/4229—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4272—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/50—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Developmental Biology & Embryology (AREA)
GBGB1608052.5A 2016-05-09 2016-05-09 T-cell receptors which recognise frameshift mutants of TGF-beta RII Ceased GB201608052D0 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
GBGB1608052.5A GB201608052D0 (en) 2016-05-09 2016-05-09 T-cell receptors which recognise frameshift mutants of TGF-beta RII
CN201780038176.8A CN109328196B (zh) 2016-05-09 2017-05-09 识别TGFβRII的移码突变体的T细胞受体
US16/099,329 US20190336529A1 (en) 2016-05-09 2017-05-09 T-cell receptors which recognise frameshift mutants of tgfbrii
KR1020187035676A KR20190016507A (ko) 2016-05-09 2017-05-09 TGFβRII의 프레임시프트 돌연변이체를 인식하는 T-세포 수용체
JP2018559282A JP2019517790A (ja) 2016-05-09 2017-05-09 ＴＧＦβＲＩＩのフレームシフト変異体を認識するＴ細胞受容体
SG11201809716VA SG11201809716VA (en) 2016-05-09 2017-05-09 T-CELL RECEPTORS WHICH RECOGNISE FRAMESHIFT MUTANTS OF TGFßRII
EP17725537.9A EP3455249B1 (en) 2016-05-09 2017-05-09 T-cell receptors which recognise frameshift mutants of tgfbetarii
MX2018013581A MX2018013581A (es) 2016-05-09 2017-05-09 Receptores de células t que reconocen mutantes de despazamiento del marco lectura de tgfbrii.
CA3024555A CA3024555A1 (en) 2016-05-09 2017-05-09 T-cell receptors which recognise frameshift mutants of tgf.beta.rii
AU2017261684A AU2017261684A1 (en) 2016-05-09 2017-05-09 T-cell receptors which recognise frameshift mutants of TGFβRII
PCT/EP2017/061087 WO2017194555A1 (en) 2016-05-09 2017-05-09 T-CELL RECEPTORS WHICH RECOGNISE FRAMESHIFT MUTANTS OF TGFßRII
EA201892217A EA201892217A1 (ru) 2016-05-09 2017-05-09 Т-КЛЕТОЧНЫЕ РЕЦЕПТОРЫ, КОТОРЫЕ РАСПОЗНАЮТ МУТАНТНЫЕ ВАРИАНТЫ СО СДВИГОМ РАМКИ СЧИТЫВАНИЯ TGFβRII
IL262873A IL262873A (en) 2016-05-09 2018-11-07 T-cell receptors which recognise frameshift mutants of tgf-beta rii

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1608052.5A GB201608052D0 (en) 2016-05-09 2016-05-09 T-cell receptors which recognise frameshift mutants of TGF-beta RII

Publications (1)

Publication Number Publication Date
GB201608052D0 true GB201608052D0 (en) 2016-06-22

Family

ID=56297359

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1608052.5A Ceased GB201608052D0 (en) 2016-05-09 2016-05-09 T-cell receptors which recognise frameshift mutants of TGF-beta RII

Country Status (13)

Country Link
US (1) US20190336529A1 (https=)
EP (1) EP3455249B1 (https=)
JP (1) JP2019517790A (https=)
KR (1) KR20190016507A (https=)
CN (1) CN109328196B (https=)
AU (1) AU2017261684A1 (https=)
CA (1) CA3024555A1 (https=)
EA (1) EA201892217A1 (https=)
GB (1) GB201608052D0 (https=)
IL (1) IL262873A (https=)
MX (1) MX2018013581A (https=)
SG (1) SG11201809716VA (https=)
WO (1) WO2017194555A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10724043B2 (en) * 2016-10-06 2020-07-28 Nantbio, Inc. Multi-pulse transfection methods and cells
US20190358263A1 (en) 2016-12-07 2019-11-28 Oslo Universitetssykehus Hf Compositions and Methods for Cell Therapy
GB201713078D0 (en) 2017-08-15 2017-09-27 Adaptimmune Ltd T Cell Modification
WO2019069125A1 (en) 2017-10-06 2019-04-11 Oslo Universitetssykehus Hf CHIMERIC ANTIGEN RECEPTORS
US12275773B2 (en) 2018-09-21 2025-04-15 Xlifesc, Ltd. High affinity cell receptor for recognizing AFP antigen
WO2020201527A1 (en) * 2019-04-04 2020-10-08 Umc Utrecht Holding B.V. Modified immune receptor constructs
GB201907663D0 (en) 2019-05-30 2019-07-17 Ab Mavatar Method for diagnosing colorectal cancer
TW202229327A (zh) * 2020-10-02 2022-08-01 美國衛生與公眾服務部 針對含有g13d突變之ras之hla第ii類限制性dq t細胞受體
WO2023050063A1 (zh) * 2021-09-28 2023-04-06 溧阳瑅赛生物医药有限公司 一种识别hla-a*02:01/e629-38的tcr及其应用
US20260070960A1 (en) 2022-09-01 2026-03-12 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies targeting hpv e6/e7 oncogenic peptide/mhc complexes
WO2024263818A2 (en) * 2023-06-20 2024-12-26 Immunova Therapeutics Llc Synthetic t cell receptors for enhancing memory (stem) t cells using new transmembranes and signaling domains
EP4733322A1 (en) * 2023-06-21 2026-04-29 Corregene Biotechnology Co., Ltd. Modified tcr constant region and use thereof in tcr fusion protein

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO315238B1 (no) * 1998-05-08 2003-08-04 Gemvax As Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy
FR2779432A1 (fr) * 1998-06-08 1999-12-03 Transgene Sa Sequence nucleique du recepteur rii du tgfb, peptide code, et utilisations
KR20120063475A (ko) * 2009-07-29 2012-06-15 글락소 그룹 리미티드 항-ｔｇｆ-베타 수용체 타입 ⅱ 단일 도메인 항체
CN103732623B (zh) * 2011-06-03 2017-09-29 佐马技术有限公司 对TGF‑β具有特异性的抗体
WO2014088432A1 (en) * 2012-12-06 2014-06-12 Callaghan Innovation Research Limited Conjugate compounds
WO2015169853A1 (en) * 2014-05-06 2015-11-12 Universitetet I Oslo Engineered invariant chain molecule for improved mhc class i loading
WO2015189267A2 (en) * 2014-06-10 2015-12-17 Universitetet I Oslo Engineered invariant chain molecule for improved mhc class i loading

Also Published As

Publication number Publication date
WO2017194555A1 (en) 2017-11-16
SG11201809716VA (en) 2018-11-29
CN109328196A (zh) 2019-02-12
AU2017261684A1 (en) 2018-12-13
KR20190016507A (ko) 2019-02-18
EP3455249B1 (en) 2023-05-03
EP3455249A1 (en) 2019-03-20
EA201892217A1 (ru) 2019-08-30
JP2019517790A (ja) 2019-06-27
IL262873A (en) 2019-01-31
US20190336529A1 (en) 2019-11-07
CN109328196B (zh) 2022-11-01
CA3024555A1 (en) 2017-11-16
MX2018013581A (es) 2019-07-04

Similar Documents

Publication Publication Date Title
GB201608052D0 (en) T-cell receptors which recognise frameshift mutants of TGF-beta RII
IL274025A (en) A new T-cell receptor
EP3102236A4 (en) Chimeric antigen receptors recognizing cancer-specific tn glycopeptide variants
EP3518944A4 (en) ADAPTIVE CHIMERIC ANTIGENT RECEPTOR T-CELL DESIGN
AP2016009445A0 (en) Muscarinic receptor agonists
IL276400A (en) Dopamine D3 receptor antagonist compounds
ZA201800483B (en) Dopamine d3 receptor antagonists having a bicyclo moiety
GB201702617D0 (en) Receptor
EP3244923A4 (en) Pro-inflammatory and adjuvant functions of toll-like receptor 4 antagonists
IL279621A (en) Cancer-specific T-cell receptors
EP3703694A4 (en) MEDICINES ANTAGONISTS OF OPIOID RECEPTORS
GB201620510D0 (en) Piston Bowl
HUE058032T2 (hu) Szétválasztó eszköz
AU201712348S (en) Cover for bowl
IL255202A0 (en) nested bowl
HK40006360A (en) T-CELL RECEPTORS WHICH RECOGNISE FRAMESHIFT MUTANTS OF TGFßRII
ZA201801216B (en) Detonator cable
GB2539108B (en) Pyrolysis device
GB201620507D0 (en) Piston bowl
HK40036636A (en) Opioid receptor antagonist prodrugs
PH32017000453S1 (en) Cover for bowl
GB201700238D0 (en) Prodrugs of an angiotensin receptor agonist
GB201701887D0 (en) Receptor
GB201700926D0 (en) Receptor
AU2016206965C1 (en) Pro-inflammatory and adjuvant functions of toll-like receptor 4 antagonists

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)